$599

Xeris completes Ph3 for stable glucagon

Xeris Pharmaceuticals has announced the completion of two Ph3 clinical trials (adults and pediatrics) and one human factors study for its stable glucagon (no reconstitution required). According to the press release, the company anticipates to submit an NDA filing by the end of Q2 ’18.

This content is for Read Less members only.
Register
Already a member? Log in here